CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice
Open Access
- 30 September 2008
- journal article
- Published by Elsevier BV in Molecular and Cellular Neuroscience
- Vol. 39 (1), 8-20
- https://doi.org/10.1016/j.mcn.2008.04.007
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington diseaseJCI Insight, 2007
- Progesterone increases brain‐derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen‐activated protein kinase‐ and phosphoinositide‐3 kinase‐dependent manner in cerebral cortical explantsJournal of Neuroscience Research, 2007
- Differential regulation and properties of MAPKsOncogene, 2007
- Mixed lineage kinases (MLKs): a role in dendritic cells, inflammation and immunity?International Journal of Experimental Pathology, 2007
- Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's diseaseNeurobiology of Disease, 2006
- Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminaseJCI Insight, 2006
- Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cellsCellular Signalling, 2006
- Mixed Lineage Kinase 3 (MLK3)-activated p38 MAP Kinase Mediates Transforming Growth Factor-β-induced Apoptosis in Hepatoma CellsJournal of Biological Chemistry, 2004
- Caspases in Huntington’s DiseaseThe Neuroscientist, 2001
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001